GW Pharma Analyst Expects $475M In Sales Of CBD Drug Expidiolex This Year

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) exceeded fourth-quarter estimates for Epidiolex sales, notching $108 million in revenue for the CBD drug, according to the company’s preliminary figures

The earnings preview triggered a brief run in the stock this week — one bulls hope to sustain after six months of declines.

The GW Pharma Analyst

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on GW Pharma with a $224 price objective. 

Benzinga’s Cannabis Capital Conference returns to Miami Feb. 24-25 with North America’s largest B2B cannabis gathering, bringing together capital, cannabis executives, thought leaders and more!

The GW Pharma Thesis

In meetings this week, GW management assured Bank of America of a positive sales trajectory for its lead drug, Epidolex, Ahmad said in a Thursday note. (See her track record here.) 

BofA anticipates $475 …

Full story available on Benzinga.com

More GW Pharma Analyst Expects $475M In Sales Of CBD Drug Expidiolex This Year